Investor information

Sentinel Oncology is a privately owned small molecule drug discovery company focusing on the discovery and development of new chemical entities for the treatment of cancer.

Sentinel has built a pipeline of small molecules designed to target hallmarks of solid tumours. In particular Sentinel is developing small molecule inhibitors that are activated selectively under tumour Hypoxia (the low oxygen environment found in all solid tumours). Our vision is to develop drugs in oncology that are void of the systemic toxicities often associated with chemotherapeutics.

The company was founded in 2005 and is located on the Cambridge Science Park, Cambridge, UK